Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Infant Bacterial Therapeutics AB ( ($SE:IBT.B) ).
Infant Bacterial Therapeutics AB presented promising clinical outcomes of their investigational product, IBP-9414, at the NEC Society Symposium in Chicago. The study showed significant reductions in mortality and severe gastrointestinal complications in preterm infants treated with IBP-9414 compared to placebo, suggesting a potential shift in the standard of care for NEC. This development has been met with optimism from both the scientific community and advocacy groups, highlighting IBT’s role in advancing NEC treatment and prevention.
More about Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) operates in the biotherapeutics industry, focusing on developing live biotherapeutic products aimed at addressing severe infant health conditions. Their primary product, IBP-9414, targets necrotizing enterocolitis (NEC) in preterm infants, a critical area of need in neonatal care.
Average Trading Volume: 10,016
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.1B
See more data about IBT.B stock on TipRanks’ Stock Analysis page.